LINC-PINT and glioblastoma: LINC-PINT, a long intergenic non-coding RNA triggered by p53, inhibits tumor cell proliferation in glioblastoma, hepatocellular carcinoma, and laryngeal squamous cell carcinoma (LSCC), making it a potential therapeutic target for tumor treatment [29–31].